Robert Marcus
JPMorgan Chase & Co, Research Division
Good morning, everyone. I’m Robbie Marcus, med tech analyst at JPMorgan. Really happy to introduce our next speaker, CEO of Zimmer Biomet, Ivan Tornos. He’ll do a presentation followed by some Q&A. Ivan.
Ivan Tornos
President, CEO & Chairman of the Board
Thank you. So good morning. The morning already started in an interesting way because I was getting my microphone on, and I was talking to Cesar, the guy in charge of IT and immediately detected the accent. Asked me where I’m from, I see Madrid, and he proceed to talk to me about how Barcelona beat Real Madrid over the weekend. So at this point, everything has to go uphill.
Look, I know that this is a busy week. I know that in the next 3 to 4 days, all of you probably will pay attention or will try to pay attention to no less than 40 or 50 presentations. So I’m going to try to summarize my entire presentation in the first minute, and then we’ll go through the slides in, let’s say, 10, 15 minutes, and then the most important part, I’d like to get going with the Q&A. And hopefully, we’ll get some questions from the audience as well.
So everything you need to know about Zimmer Biomet in 2026, hard to believe we already are in 2026. Look, we are very pleased, very encouraged with the progress we made over the last 5 years. It was
Credit: Source link
